Capital raised by GT Biopharma
3 Form D filings · first filed Feb 2025 · San Francisco, CA
Chief Financial Officer
Signatory on GT Biopharma's Form D filings · $7.2M raised across 3
Alan Urban is on file as Chief Financial Officer at GT Biopharma in San Francisco, CA. GT Biopharma has 3 Form D filings on record, $7.2M raised in total. Alan Urban appears as a signatory on the company's filings.
GTB-3650 is a TriKE therapeutic agent specifically targeting CD33-expressing hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The product is designed to engage the patient’s immune cells to more effectively target and kill cancer cells, thereby enhancing the therapeutic prospects for patients with challenging forms of blood cancer.
